Drugs / FXIII concentrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01545635 Comparator | Mar 2012 → Feb 2016 | brain injury | Medical University Innsbruck | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXIII concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01545635 ↗ |
| Known as | Fibrogammin P | “FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected...” NCT01545635 ↗ |
| Route | Intravenous | “Kind of application: Intravenously” NCT01545635 ↗ |